A present-day study demonstrates the strengthening of systemic anti-tumor effects in various preclinical tumor models, with a vaccinia virus that coexpresses a PD-L1 inhibitor and GM-CSF (VV-iPDL1/GM). The gene discussed is CD274; the disease is neoplasm.